<DOC>
	<DOCNO>NCT01196975</DOCNO>
	<brief_summary>This study design test immunogenicity safety investigational influenza vaccine , adult compare two influenza vaccine . This study also evaluate lot-to-lot consistency three vaccine lot .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity GSK Biologicals ' Seasonal Influenza Vaccine Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol A male female 18 year age old , stable health , establish medical history physical examination enter study . Written inform consent obtain subject . Access consistent mean telephone contact , may either home workplace , land line , mobile , NOT pay phone multipleuser device . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Use investigational / nonregistered product study vaccine within 30 day study vaccination plan use study period . Planned administration administration license vaccine within 30 day study vaccination . Prior receipt 2010/2011 influenza vaccine . Receipt investigational approve influenza vaccine within six month first study visit . Any known suspected allergy constituent influenza vaccine ; history anaphylactictype reaction constituent vaccine ; history severe adverse reaction previous influenza vaccine . History reaction hypersensitivity likely exacerbate component vaccine . History GuillainBarre syndrome within 6 week receipt prior inactivate influenza virus vaccine . Presence evidence substance abuse neurological psychiatric diagnosis , even clinically stable , deemed investigator render potential subject unable / unlikely provide accurate safety report . Acute , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , base history physical examination . Presence significant uncontrolled chronic medical neuropsychiatric illness , base history physical examination Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Any significant disorder coagulation treatment Coumadin derivatives heparin Chronic administration immunosuppressant immunemodifying drug within 3 month prior first vaccine/product dose . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Pregnant lactate female . Fever time enrolment . Acute disease time enrolment Any condition , opinion Investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Influenza</keyword>
</DOC>